Black Diamond Therapeutics Future Growth
Future criteria checks 0/6
Black Diamond Therapeutics's earnings are forecast to decline at 7.6% per annum while its annual revenue is expected to grow at 77.3% per year. EPS is expected to grow by 5.2% per annum.
Key information
-7.6%
Earnings growth rate
5.2%
EPS growth rate
Biotechs earnings growth | 23.7% |
Revenue growth rate | 77.3% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 08 Apr 2024 |
Recent future growth updates
Recent updates
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 31Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
Jan 12Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation
Oct 26Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 05We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 16Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?
Oct 02Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
Jul 02We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully
Jan 16We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely
Jun 11Black Diamond Therapeutics EPS misses by $0.16
May 07We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Feb 26What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition
Jan 05Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?
Dec 01Black Diamond nominates development candidate for glioblastoma program
Nov 20Black Diamond Therapeutics EPS beats by $0.02
Nov 10Black Diamond Therapeutics: One To Watch In Precision Oncology Space
Oct 23Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 4 | -145 | -133 | -116 | 5 |
12/31/2025 | N/A | -121 | -106 | -99 | 5 |
12/31/2024 | N/A | -94 | -86 | -69 | 6 |
12/31/2023 | N/A | -82 | -67 | -67 | N/A |
9/30/2023 | N/A | -84 | -75 | -75 | N/A |
6/30/2023 | N/A | -83 | -73 | -73 | N/A |
3/31/2023 | N/A | -87 | -77 | -77 | N/A |
12/31/2022 | N/A | -91 | -85 | -85 | N/A |
9/30/2022 | N/A | -96 | -88 | -87 | N/A |
6/30/2022 | N/A | -109 | -99 | -97 | N/A |
3/31/2022 | N/A | -121 | -107 | -104 | N/A |
12/31/2021 | N/A | -126 | -103 | -100 | N/A |
9/30/2021 | N/A | -122 | -94 | -92 | N/A |
6/30/2021 | N/A | -105 | -78 | -77 | N/A |
3/31/2021 | N/A | -85 | -65 | -65 | N/A |
12/31/2020 | N/A | -67 | -52 | -52 | N/A |
9/30/2020 | N/A | -55 | -44 | -44 | N/A |
6/30/2020 | N/A | -46 | -38 | -38 | N/A |
3/31/2020 | N/A | -44 | -29 | -29 | N/A |
12/31/2019 | N/A | -35 | -25 | -25 | N/A |
9/30/2019 | N/A | -28 | -20 | -20 | N/A |
6/30/2019 | N/A | -22 | -16 | -16 | N/A |
3/31/2019 | N/A | -11 | -13 | -13 | N/A |
12/31/2018 | N/A | -9 | -9 | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BDTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BDTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BDTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BDTX is forecast to have no revenue next year.
High Growth Revenue: BDTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BDTX's Return on Equity is forecast to be high in 3 years time